Metraipolis › archive › dc_30dd625dc423

Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma — Europe PMC PMID:40959072

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40959072
DOI
10.3389/fimmu.2025.1629224
License (as archived)
solo-consultazione
Archived
2026-11-10T05:53:36.299Z
SHA-256 of the archived text
3ca0755722cb9bb082e2fd253ef4853877a68a368e0077c5341377daec3add87
Stable URL of this page
https://metraipolis.com/documento/dc_30dd625dc423

How to cite

Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma — Europe PMC PMID:40959072 — Europe PMC (en), https://europepmc.org/article/MED/40959072 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_30dd625dc423 (Metraipolis archive dc_30dd625dc423, sha256 3ca0755722cb9bb082e2fd253ef4853877a68a368e0077c5341377daec3add87)
BibTeX
@misc{dc30dd625dc423,
  title = {Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma — Europe PMC PMID:40959072},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40959072},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_30dd625dc423; sha256 3ca0755722cb9bb082e2fd253ef4853877a68a368e0077c5341377daec3add87},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40959072. Agents can read the archived copy with the MCP tool read_document.